Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Oxycodone controlled release - Purdue Pharma

Drug Profile

Oxycodone controlled release - Purdue Pharma

Alternative Names: OxiContin; Oxycodone controlled release - Purdue; Oxycodone extended release - Purdue; Oxycodone hydrochloride controlled-release; OxyContin; OxyContin Neo; OxyContinTR; OxyNeo

Latest Information Update: 11 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Purdue Pharma
  • Developer Mundipharma International; Napp Pharmaceutical Group; Purdue Pharma; Shionogi
  • Class Alkaloids; Morphine derivatives; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid delta receptor agonists; Opioid kappa receptor agonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Cancer pain; Pain; Postoperative pain

Most Recent Events

  • 11 Jul 2019 No development reported - Phase-III for Pain (In children) in Spain, Romania, United Kingdom, Hungary, New Zealand, Israel, Greece, USA (PO) before July 2019
  • 28 Aug 2018 Assertio Therapeutics signs settlement agreement with Purdue Pharma as a follow-up to its patent infringement lawsuit (related to oxycodone controlled release) filed in U.S. District Court for the District of New Jersey
  • 07 Sep 2017 Mundipharma completes a phase I trial in Pain in China (NCT03403504)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top